On the risk of delisting of ordinary shares of Eagle Pharmaceuticals, Inc. (EGRX)

The International Trading System Limited (hereinafter — ITS) hereby informs on the delisting risk of ordinary shares of Eagle Pharmaceuticals, Inc. (ISIN US2697961082, hereinafter — Shares, QI) from The Nasdaq Stock Market LLC (hereinafter — Nasdaq).

Information on delisting risk of ordinary shares by Nasdaq 

On November 29, 2023 Eagle Pharmaceuticals, Inc. (hereinafter — the Company) submitted Current report on Form 8-K to The United States Securities and Exchange Commission (the “SEC”). According to the report, on November 27, 2023 the Company received a delinquency notification letter (the “Notice”) from the Listing Qualifications Department of  Nasdaq notifying the Company that due to the delay in filing the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all periodic financial reports with the SEC.

The Notice provides that the Company has 60 calendar days from the date of the Notice, or until January 26, 2024, to submit to Nasdaq a plan to regain compliance with the Rule. If Nasdaq accepts the plan, Nasdaq may grant the Company an exception of up to 180 calendar days from the due date of the Form 10-Q, or until May 7, 2024, to regain compliance. For more information, please refer to the report available on the SEC website.

Information regarding possible actions to be taken by ITS Ltd.

ITS Ltd. (hereinafter – ITS) conducts regular monitoring of the relevant information disclosed by the Company. Delisting of the Company’s securities (hereinafter – Qualified Investments) by Nasdaq will be considered to costitute a breach of the ITS Regulations on admitting financial instruments to trading and result in termination of trading in the Qualified Investments on ITS. In case Nasdaq decides to suspend trading in the Company's securities until the date of their delisting on Nasdaq, ITS may make a similar decision.